论文部分内容阅读
目的观察复方青秦液对尿酸性肾病大鼠肾组织Toll样受体TLR2、TLR4基因及蛋白表达的影响,探讨其肾脏保护的机制。方法将55只SD大鼠随机分为正常组5只;模型组、阳性药组及中药大、中、小剂量组,每组各10只,用腺嘌呤灌胃伴饲酵母造模。正常组及模型组每日灌胃蒸馏水10 mL/kg,阳性药组每日灌胃别嘌醇9.33 mg/kg,中药大、中、小剂量组每日灌胃复方青秦液3.77、1.89、0.94 g/kg,连续6周。4周和6周时分别处死部分大鼠,留取肾脏组织,RT-PCR检测TLR2、TLR4 mRNA转录水平,Western blot测定TLR2、TLR4蛋白表达水平,免疫组化测定TLR4蛋白表达水平。结果与正常组同期比较,4、6周模型组大鼠肾组织TLR4 mRNA转录水平、TLR2、TLR4蛋白表达水平升高(P<0.05,P<0.01)。与模型组同期比较,4、6周复方青秦液各剂量组TLR2、TLR4mRNA转录水平差异均无统计学意义(P>0.05),6周复方青秦液各剂量组TLR2、TLR4蛋白表达水平降低(P<0.05,P<0.01)。结论复方青秦液可通过降低TLR2、TLR4蛋白表达以抑制肾组织炎性病理损伤。
Objective To observe the effects of compound qing qin liquid on the expression of TLR2 and TLR4 gene and protein in renal tissue of rats with uric acid nephropathy and to explore its mechanism of renal protection. Methods Fifty-five Sprague-Dawley rats were randomly divided into normal group (n = 5), model group (n = 10), positive group (n = 10) and middle and small dose group (n = 10). The normal group and model group were fed with distilled water 10 mL / kg daily, the positive drug group was perfused with allopurinol 9.33 mg / kg daily, and the large, medium and small dose groups of Chinese medicine were orally administered with compound Qingqin liquid 3.77,1.89, 0.94 g / kg for 6 weeks. At 4 weeks and 6 weeks, some rats were sacrificed and the kidneys were removed. The transcription levels of TLR2 and TLR4 mRNA were detected by RT-PCR. The expressions of TLR2 and TLR4 protein were detected by Western blot and the expressions of TLR4 protein by immunohistochemistry. Results Compared with the normal control group, the mRNA expression of TLR4, the expression of TLR2 and TLR4 in renal tissue of model group were significantly increased at 4 and 6 weeks (P <0.05, P <0.01). Compared with the model group, there was no significant difference in the TLR2 and TLR4 mRNA transcription levels between the four groups at 4 and 6 weeks (P> 0.05). The TLR2 and TLR4 protein expression levels were decreased (P <0.05, P <0.01). Conclusion Qingqin liquid can inhibit the inflammatory pathological changes of renal tissue by decreasing the expression of TLR2 and TLR4.